Loading
Showed that PD-L1 is the ligand for PD-1 and that the pair switches T cells off, the foundation of checkpoint immunotherapy.
Gordon Freeman, with Arlene Sharpe and Tasuku Honjo, identified PD-L1 and PD-L2 as the ligands of PD-1 in 2000 and 2001 and showed that engagement inhibits T-cell activation, defining the pathway that pembrolizumab, nivolumab and atezolizumab block. He holds foundational patents on PD-1 pathway blockade and shared the Warren Alpert Prize; his laboratory continues to study checkpoint mechanisms.
| Title | Journal | Year |
|---|---|---|
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Journal of Experimental Medicine | 2000 |
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Nature Immunology | 2001 |
| Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer | New England Journal of Medicine | 2012 |
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, PD-L1, PD-1, Immune checkpoint inhibitors and the tags immunotherapy, discovery.
Shares Dana-Farber Brigham Cancer Center, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-L1, PD-1, Immune checkpoint inhibitors.
Shares PD-L1, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Dana-Farber Brigham Cancer Center, PD-1, Immune checkpoint inhibitors.
Shares PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, Dana-Farber Brigham Cancer Center, PD-1, Immune checkpoint inhibitors.